Loading stock data…
INCY
$97.47+0.33 (+0.34%)
Pre-Market$97.46-0.01 (-0.01%)· Last close May 5
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incyte Corporation in the Healthcare sector is trading at $97.47. The stock is currently 13% below its 52-week high of $112.29, remaining 3.9% above its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why INCY maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$97.47
Potential Upside
43.3%
Whystock Fair Value$139.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Buy
Mean target$108.50+11.3%
Range$71.00 – $135.00
Fundamentals
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycyth...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.03B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.92
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.85%
Volume
Today's trading volume
926,500
Recent News
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings
Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitinib could be administered in the early stages of hidradenitis suppurativa, rather than as a post-biologic oral alternative. H.C. Wainwright mentioned a […]
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Incyte Corporation ( NASDAQ:INCY ) came out with a strong set of quarterly numbers that could potentially...
Company News for Apr 29, 2026
Companies In The News Are: GM, KO, CNC, INCY.
Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...
Incyte Corp (INCY) reports a robust start to 2026 with a 21% revenue increase and advances in its late-stage pipeline, despite challenges in diversifying beyond Jakafi.
Incyte Wavers As Growth Questions Plague Its Up-And-Coming Drug
Incyte stock wavered but closed up Tuesday as growth questions surrounding its eczema cream, Opzelura, plagued its first-quarter beat.